NASDAQ: TXMD
TherapeuticsMD, Inc.CIK 0000025743 · SIC 2834 · Pharmaceutical Preparations
Throughout this Annual Report on Form 10-K (“2025 10-K Report”), the terms “we,” “us,” “our,” “TherapeuticsMD,” “the Company,” or “our company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries vitaMedMD, LLC, a Delaware… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (CNXC 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TXMD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 13, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(Unaudited - in thousands, except per share data)
| Description | Three months ended September 30, 2026 | Three months ended September 30, 2025 | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|---|---|
| Revenue, net: | ||||
| License revenue | 1,259 | 784 | 2,852 | 2,129 |
| Operating expenses: | ||||
| General and administrative | 1,641 | 1,518 | 4,571 | 4,560 |
| Write-off of patents | — | 32 | 13 | 120 |
| Depreciation and amortization | 97 | 96 | 286 | 287 |
| Total operating expenses | 1,738 | 1,646 | 4,870 | 4,967 |
| Loss from operations | (479) | (862) | (2,018) | (2,838) |
| Other income: | ||||
| Interest income, net | 77 | 32 | 187 | 91 |
| Sublease income | 521 | 534 | 1,561 | 1,320 |
| Miscellaneous income | 382 | 346 | 1,038 | 1,354 |
| Total other income, net | 980 | 912 | 2,786 | 2,765 |
| Income (loss) from continuing operations before income taxes | 501 | 50 | 768 | (73) |
| Income tax benefit | — | — | — | 32 |
| Income (loss) from continuing operations, net of income taxes | 501 | 50 | 768 | (41) |
| (Loss) income from discontinued operations, net of income taxes | (10) | 102 | (27) | 91 |
| Net income | 491 | 152 | 741 | 50 |
| Income (loss) per common share, basic and diluted: | ||||
| Continuing operations | 0.04 | 0.00 | 0.07 | (0.00) |
| Discontinued operations, net | (0.00) | 0.01 | (0.00) | 0.01 |
| Net income per common share, basic and diluted | 0.04 | 0.01 | 0.06 | 0.00 |
| Weighted average common shares, basic | 11,574 | 11,574 | 11,574 | 11,567 |
| Weighted average common shares, diluted | 11,643 | 11,574 | 11,644 | 11,567 |
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
| Description | September 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Assets: | ||
| Current assets: | ||
| Cash and cash equivalents | 10,447 | 7,483 |
| Royalty receivable, current portion | 3,412 | 3,525 |
| Prepaid and other current assets | 3,557 | 3,437 |
| Total current assets | 17,416 | 14,445 |
| License rights and other intangible assets, net | 3,462 | 3,761 |
| Right of use assets, net | 4,589 | 5,293 |
| Royalty receivable, long term | 12,095 | 13,713 |
| Other non-current assets | 370 | 444 |
| Total assets | 37,932 | 37,656 |
| Liabilities and stockholders’ equity: | ||
| Current liabilities: | ||
| Accounts payable | 377 | 377 |
| Accrued expenses and other current liabilities | 2,205 | 1,741 |
| Current liabilities of discontinued operations | 2,667 | 2,667 |
| Total current liabilities | 5,249 | 4,785 |
| Operating lease liabilities | 4,210 | 5,122 |
| Other non-current liabilities | 849 | 873 |
| Total liabilities | 10,308 | 10,780 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Common stock, par value $0.001; 640,000 and 32,000 shares authorized, 11,574 and 11,574 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 979,263 | 979,256 |
| Accumulated deficit | (951,650) | (952,391) |
| Total stockholders’ equity | 27,624 | 26,876 |
| Total liabilities and stockholders’ equity | 37,932 | 37,656 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Unaudited - in thousands)
| Description | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | 741 | 50 |
| Less: (loss) income from discontinued operations, net of income taxes | (27) | 91 |
| Net income (loss) from continuing operations | 768 | (41) |
| Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities: | ||
| Depreciation and amortization | 286 | 287 |
| Write-off of patents | 13 | 119 |
| Share-based compensation costs | 7 | 24 |
| Amortization of right of use assets | 704 | 587 |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets | (120) | (188) |
| Other assets | 1,805 | 1,401 |
| Accounts payable | — | 5 |
| Accrued expenses and other current liabilities | 369 | 509 |
| Lease liabilities | (817) | (752) |
| Other non-current liabilities | (24) | 128 |
| Total adjustments | 2,223 | 2,120 |
| Net cash provided by continuing operating activities | 2,991 | 2,079 |
| Discontinued operations: | ||
| Net cash used in operating activities | (27) | (23) |
| Net cash used in discontinued operations | (27) | (23) |
| Net increase in cash and cash equivalents | 2,964 | 2,056 |
| Cash and cash equivalents, beginning of period | 7,483 | 5,059 |
| Total cash and cash equivalents, end of period | 10,447 | 7,115 |
Amounts as printed on the EDGAR/iXBRL face — (Unaudited - in thousands, except per share data); (In thousands, except per share data); (Unaudited - in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
About TherapeuticsMD, Inc.
Source: Item 1 (Business) from the 10-K filed March 30, 2026. Description as filed by the company with the SEC.
Item 1. Business
Overview
Throughout this Annual Report on Form 10-K (“2025 10-K Report”),
the terms “we,” “us,” “our,” “TherapeuticsMD,” “the Company,” or “our
company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries
vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), and BocaGreenMD, Inc., a Nevada corporation (“BocaGreen”).
TherapeuticsMD is a pharmaceutical royalty company that owns or has
rights to trademarks, service marks, or trade names that were previously used in connection with the operation of its business, or are
now licensed by another party, including TherapeuticsMD®, vitaMedMD®, BocaGreenMD®, BIJUVA®, and IMVEXXY®, which are
protected under applicable intellectual property laws and are the property of the Company. This 2025 10-K Report also contains trademarks,
trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks,
trade names and service marks referred to in this 2025 10-K Report may appear without the ®, ™ or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right
of the applicable licensor to these trademarks, trade names, and service marks. We do not intend our use or display of other parties’
trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement
or sponsorship of us by, these other parties.
Read full description ↓
In addition, this 2025 10-K Report includes market and industry data
that we obtained from periodic industry publications, third-party studies and surveys, government-agency sources, filings of public companies
in our industry, and internal-company surveys. Industry publications and surveys generally state that their information has been obtained
from sources believed to be reliable. Although we believe that the industry and market data below is reliable as of the date of this
2025 10-K Report, this information could prove to be inaccurate as a result of a variety of matters.
Forward-looking statements
This 2025 10-K Report contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties.
For example, statements regarding our operations, financial position, business strategy, exploration of potential strategic alternatives,
and other plans and objectives for future operations, and assumptions and predictions about future demand, marketing, expenses and sales
are all forward-looking statements. These statements may be found in the items of this 2025 10-K Report entitled “Business”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as in this 2025
10-K Report generally. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,”
“estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,”
“may,” “will,” “could,” “would,” “should,” “expect,” or the negative
of such terms or other comparable terminology.
We have based these forward-looking statements on our current expectations
and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are
reasonable, based on information available to us on the date of this 2025 10-K Report, but we cannot assure you that these assumptions
and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking
statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from
those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include,
but are not limited to, competition from other businesses, market and general economic factors, and the other risks discussed in Item
1A of this 2025 10-K Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto
included in this 2025 10-K Report.
1
We have identified some of the important factors that could cause
future events to differ from our current expectations and they are described in this 2025 10-K Report in the section entitled “Risk
Factors” that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this
2025 10-K Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect,
actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly
announce the results of any revisions to any statements to reflect new information or future events or developments.
Our company
TherapeuticsMD was previously a women’s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the “Closing
Date”), we completed a transaction (the “Mayne Transaction”) with Mayne Pharma LLC, a Delaware limited liability company
(“Mayne Pharma”) and subsidiary of Mayne Pharma Group Limited, an Australian public company (“Mayne Pharma Group”),
in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription
prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the “Licensed Products”) in the
United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA®
(together with the Licensed Products, collectively, the “Products”) in the United States and its possessions and territories,
and (iii) sold certain other assets to Mayne Pharma in connection therewith.
In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the “Mayne License Agreement”), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.
Under the Mayne License Agreement, Mayne Pharma agreed to pay us one-time
milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar year reach
$100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach $200.0 million
and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0 million. Further,
Mayne Pharma agreed to pay us royalties on net sales of all Products in the United States at a royalty rate of 8.0% on the first $80.0
million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for a period of 20 years
following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the
expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States.
Mayne Pharma agreed to pay us minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation at an annual rate
of 3%, subject to certain further adjustments, including as described below (the “Minimum Annual Royalty”). Upon the expiry
of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty
free license for the Licensed Products.
Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the “Transaction Agreement”), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council’s consent, our exclusive license from the Population
Council to commercialize ANNOVERA (the “Transferred Assets”).
The total consideration from Mayne Pharma to TherapeuticsMD for the
purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement was
(i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition of
net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments, (iii) a cash payment
of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment (as defined below)
and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended.
2
On the Closing Date, TherapeuticsMD and Mayne Pharma entered into
Amendment No. 1 to the Mayne License Agreement (the “Mayne License Agreement Amendment”). Pursuant to the Mayne License Agreement
Amendment, Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced
the first four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to
$257 thousand per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such
quarterly royalty payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne Pharma for the assumed
obligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed, Mayne
Pharma reduced the second quarterly royalty payment otherwise payable to us by an additional $0.6 million, and in August 2023 we remitted
the remaining consideration of $0.9 million.
As part of the transformation that included the Mayne License Agreement,
all results associated with former commercial operations have been reflected as discontinued operations in our consolidated financial
statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations
in our consolidated balance sheets.
See “Note 2. Discontinued Operations” to the consolidated
financial statements included in this 2025 10-K Report for further details.
The Company also has license agreements with strategic partners to
commercialize IMVEXXY and BIJUVA outside of the U.S.
●
In July 2018, we entered into a license and supply
agreement (the “Knight License Agreement”) with Knight Therapeutics Inc. (“Knight”) pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight obtained regulatory approval
for IMVEXXY and BIJUVA and began commercialization efforts in 2024.
●
In June 2019, we entered into an exclusive license
and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) to commercialize
IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured regulatory approval for BIJUVA in
certain European countries and began commercialization efforts in those countries.
●
In December 2024, we transferred the right to commercialize
IMVEXXY and BIJUVA in Israel from Knight to Theramex.
Employees
As of December 31, 2025, we employed one full-time employee primarily
engaged in an executive position. We have engaged external consultants who support our relationship with current partners and assist
with certain financial, IT, legal, and regulatory matters and the continued wind-down of our historical business operations. On August
15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler serves as our Principal
Financial and Accounting Officer.
Going concern
On the Closing Date of the Mayne Transaction, we repaid all obligations
under the Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent,
the various lenders from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the
“Financing Agreement”) and the Financing Agreement was terminated.
Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise capital to provide additional liquidity to fund our operations. To address our capital needs, we may pursue various
equity and debt financing and other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked,
or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten
public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including
the market price of our common stock and our available authorized shares.
3
To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.
On May 1, 2023, we entered into a Subscription Agreement (the “Subscription
Agreement”) with Rubric Capital Management LP (“Rubric”), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our “Common Stock”),
from time to time during the term of the Subscription Agreement at a purchase price of the five-day volume-weighted average price of the
Common Stock at the time of the sale of such shares of Common Stock, at an aggregate purchase price of up to $5,000,000. On June 29, 2023,
we issued and sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received
gross proceeds of $1.15 million from the draw-down, before expenses. On November 15, 2023, Rubric drew an additional 877,192 shares of
Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from the draw-down before expenses. There
were no drawdowns in 2025 and 2024.
In February 2024, we received Mayne Pharma’s calculation of the
net working capital allowances for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement, which differed
significantly from our estimate of the allowances. We continue to believe our estimated allowances for payer rebates and wholesale distributor
fees are reasonable. In August 2024 and in February 2025, we also received information from Mayne Pharma pertaining to the net working
capital allowance for returns that differs significantly from our estimate of the allowance.
On April 8, 2025, we filed a lawsuit against Mayne
Pharma in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of
contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne
Pharma’s actions in relation to the License Agreement and the Transaction Agreement, primarily relating to the net working capital
allowances and certain actions or inactions by Mayne Pharma relating thereto. On June 20, 2025, we filed an amended complaint against
Mayne Pharma and on July 22, 2025, Mayne Pharma filed a motion to dismiss the Mayne Lawsuit. On March 23, 2026, a magistrate judge recommended
that the court grant-in-part and deny-in-part Mayne Pharma’s motion to dismiss. The magistrate judge recommended granting Mayne’s
motion to dismiss our claims for breach of the covenant of good faith and fair dealing, certain of our breach of contract claims and our
claim for fraudulent inducement, but recommended the court grant us leave to amend the fraudulent inducement claim. The magistrate judge
recommended denying Mayne’s motion to dismiss our other claims. The magistrate judge further recommended the court stay the Mayne
Lawsuit while the parties submit the net working capital claims to a dispute resolution process. The parties have 14 days to object to
these recommendations.
On May 30, 2025, Mayne Pharma filed a lawsuit against us in the United
States District Court for the District of Delaware (the “Mayne Countersuit” and, together with the Mayne Lawsuit, the “Mayne
Lawsuits”) seeking damages for breach of contract and fraudulent inducement related to the Transaction Agreement. As part of the
Mayne Countersuit, Mayne Pharma also made certain indemnification demands under the Transaction Agreement, which we dispute. On July 28,
2025, we filed a motion to dismiss the fraudulent inducement claim in the Mayne Countersuit. On March 23, 2026, a magistrate judge recommended
that the court grant our motion to dismiss Mayne Pharma’s claim for fraudulent inducement, but recommended the court deny our motion
to dismiss Mayne Pharma’s other claims. The parties have 14 days to object to this recommendation. As of December 31, 2025, we believed
no additional accrual was required for such claims, as we could not reasonably estimate a range of loss.
The outcome of this matter is uncertain at this point. As a result,
we cannot reasonably estimate a range of loss, and accordingly, we have not accrued any additional liability associated with Mayne Pharma’s
allowance calculation for payer rebates and wholesale distributor fees, particularly as we believe the outcome of this matter to be intertwined
with the resolution of the net working capital allowance for returns.
As of December 31, 2025, we also believed no additional accrual was
required for amounts that may be owed for the allowance for returns under the Transaction Agreement. We have not recorded any contingent
gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital items as
changes to estimated amounts owed or amounts due from Mayne Pharma may be material.
If Mayne Pharma’s sales of Licensed Products grow more slowly
than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement is greater than our
current estimates, if the outcome of the Mayne Lawsuits is worse than we anticipate, if we are unsuccessful with future financings or
the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient
to satisfy our liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets
raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of the financial
statements included in this 2025 10-K Report.
The accompanying consolidated financial statements included in this
2025 10-K Report do not include any adjustments that might be necessary if we are unable to continue as a going concern.
Portfolio of our royalty-bearing products
On December 30, 2022, we changed our business to become a pharmaceutical
royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities
in the relevant territories. On December 30, 2022, we granted an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription
prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned our exclusive license to commercialize ANNOVERA
to Mayne Pharma.
4
IMVEXXY (estradiol vaginal inserts), 4-μg and 10-μg
This pharmaceutical product is for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. As part of the
FDA’s approval of IMVEXXY, we committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer
in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.
On December 30, 2022, we granted an exclusive license to commercialize
IMVEXXY in the United States and its possessions and territories to Mayne Pharma. We also have entered into licensing agreements with
third parties to market and sell IMVEXXY outside of the U.S. We entered into the Knight License Agreement, with Knight pursuant to which,
we granted Knight an exclusive license to commercialize IMVEXXY in Canada and Israel. We entered into the Theramex License Agreement
with Theramex pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY for human use outside of the U.S.,
except for Canada and Israel. In December 2024, we transferred the right to commercialize IMVEXXY in Israel from Knight to Theramex.
The FDA has also asked the sponsors of other vaginal estrogen products
to participate in the observational study. In connection with the observational study, we would have been required to provide progress
reports to the FDA on an annual basis. The obligation to conduct this study was transferred to Mayne Pharma as part of the Mayne License
Agreement.
BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg
This pharmaceutical product is the first and only FDA approved bioidentical
hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor
symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
On December 30, 2022, we granted an exclusive license to commercialize
BIJUVA in the United States and its possessions and territories to Mayne Pharma. We also have entered into the Knight License Agreement
with Knight pursuant to which we granted Knight an exclusive license to commercialize BIJUVA in Canada and Israel. We have entered into
the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA for human
use outside of the U.S., except for Canada and Israel. In December 2024, we transferred the right to commercialize BIJUVA in Israel from
Knight to Theramex.
ANNOVERA (segesterone acetate (“SA”) and ethinyl estradiol
(“EE”) vaginal system)
This pharmaceutical product is a one-year ring-shaped contraceptive
vaginal system (“CVS”) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that
can prevent pregnancy for up to a total of 13 cycles (one year).
On December 30, 2022, we assigned our exclusive license to commercialize
ANNOVERA in the United States and its possessions and territories to Mayne Pharma.
Prenatal vitamin products
On December 30, 2022, we granted an exclusive license to commercialize,
in the United States and its possessions and territories, our prescription prenatal vitamin product lines under our vitaMedMD brand name
and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD prenatal name to Mayne
Pharma.
5
Sales concentration
Our business model is dependent on third parties achieving specified
milestones and product sales. For information on the concentration of licenses of our products, see “Note 9. Revenue” to the
consolidated financial statements included in this 2025 10-K Report. Currently, the Company collects license revenue from three licensees.
Seasonality
The pharmaceutical markets in which we license our products are not
subject to seasonal sales fluctuations. However, our license revenues for the first quarter of each year can be negatively affected by
the annual reset of high-deductible commercial insurance plans.
Manufacturing of our licensed products
As of December 30, 2022, we were no longer responsible for any manufacturing
and have no manufacturing contracts. All manufacturing responsibility of our licensed and assigned products has been transferred to our
licensees.
Research and development
As of December 30, 2022, we no longer conduct any research and development
activities. Historically, our product development programs were concentrated in advanced hormone therapy pharmaceutical products.
Intellectual property
Patents and trademarks
Our success depends, in part, on our ability to obtain patents, maintain
trade-secret protection, and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one way
we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and
contractual restrictions to protect our products and to maintain our competitive position. We are diligently seeking ways to protect our
intellectual property through various legal mechanisms in relevant jurisdictions. Where permitted, patents for our hormone therapy drug
products have been submitted to the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the
Orange Book).
As of December 31, 2025, we have many domestic and foreign patents
that cover our licensed products, including many for each of BIJUVA and IMVEXXY that are Orange Book listed for the licensed products.
We hold multiple U.S. trademark registrations and have numerous pending
trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however,
it is subject to challenge by others claiming first use in the mark in some or all the areas in which it is used. Federally registered
trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly as trademarks, subject
to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents
and trademarks are valuable and provide us certain benefits in marketing our products.
We intend to actively protect our intellectual property with patents,
trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce,
and defend our patents, trademarks, and proprietary technology, including those licensed by Mayne Pharma, Knight and Theramex, with our
licensees to the extent permitted under their respective license agreements. The loss, by expiration or otherwise, of any one patent
may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming,
even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that
a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the development
of our products or pay licensing fees to account for patent rights of third parties. See “– Pharmaceutical Regulation –
Regulatory Exclusivity” below for information regarding our intellectual property and challenges to that intellectual property.
While we seek broad coverage under our patent applications, there
is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition,
patents expire, and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially
issued patents will adequately protect our intellectual property.
6
Mayne Pharma licensed US patents and trademarks for our commercial
products. Under the terms of the Mayne License Agreement, Mayne Pharma exclusively took over prosecution of our US patent and trademark
portfolio and enforcement of our licensed patents and trademarks.
Government regulation
In the U.S., the FDA regulates pharmaceuticals, biologics, medical
devices, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and its implementing regulations.
Although we are not currently engaged in research, development, manufacturing, or commercial distribution activities, the products from
which we derive royalties are also subject to other federal, state, and local statutes and regulations, including federal and state consumer
protection laws, laws regarding pricing transparency, laws requiring the implementation of compliance programs, laws requiring the reporting
of payments or other transfers of value to HCPs or other healthcare professionals, laws governing the financial relationships between
manufacturers and HCPs or other referral sources and industry stakeholders, laws protecting the privacy of health-related information,
laws restricting items and services of value provided to patients, and laws prohibiting unfair and deceptive acts and trade practices.
See also “